-
Mashup Score: 2
Accumulation of metabolic risk factors was associated with higher risk of MACE in patients with recent acute coronary syndrome. Alirocumab reduced MACE consistently, but aRR increased with number of metabolic risk factors.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 6
Accumulation of metabolic risk factors was associated with higher risk of MACE in patients with recent acute coronary syndrome. Alirocumab reduced MACE consistently, but aRR increased with number of metabolic risk factors.
Categories: Endocrinology, Latest HeadlinesTweet-
#Metabolic risk factors and effect of #alirocumab on #cardiovascular events after acute #coronary syndrome: a post-hoc analysis of the #ODYSSEY OUTCOMES randomised controlled trial https://t.co/exUIR7Tdp2 #ACS #CVD #PCSK9 inhibitor
-
-
Mashup Score: 0
Accumulation of metabolic risk factors was associated with higher risk of MACE in patients with recent acute coronary syndrome. Alirocumab reduced MACE consistently, but aRR increased with number of metabolic risk factors.
Categories: Endocrinology, Latest HeadlinesTweet-
#Metabolic risk factors and effect of #alirocumab on #cardiovascular events after acute #coronary syndrome: a post-hoc analysis of the #ODYSSEY OUTCOMES randomised controlled trial https://t.co/exUIR7Tdp2 #PCSK9 inhibitor #ACS
-
-
Mashup Score: 3
Accumulation of metabolic risk factors was associated with higher risk of MACE in patients with recent acute coronary syndrome. Alirocumab reduced MACE consistently, but aRR increased with number of metabolic risk factors.
Categories: Endocrinology, Latest HeadlinesTweet-
Online—Metabolic risk factors and effect of #alirocumab on #cardiovascular events after acute coronary syndrome: a post-hoc analysis of the #ODYSSEY OUTCOMES randomised controlled trial https://t.co/exUIR7Tdp2 #ACS #PCSK9 inhibitor
-
-
Mashup Score: 1Targeting PCSK9 inhibitors to those who will benefit most - 2 year(s) ago
In The Lancet Diabetes & Endocrinology, Petr Ostadal and colleagues report a post-hoc subgroup analysis of the ODYSSEY OUTCOMES trial assessing the contribution of metabolic risk factors to future cardiovascular events in patients with recent acute coronary syndrome.1 This large cardiovascular outcome trial, describes the benefits of additional LDL cholesterol reduction with the PCSK9 inhibitor…
Categories: Endocrinology, Latest HeadlinesTweet-
Traci A Turner & Evan A Stein comment: Targeting #PCSK9 inhibitors to those who will benefit most https://t.co/5plRd3SdPg #alirocumab #ACS #cardiovascular #ODYSSEY OUTCOMES
-
-
Mashup Score: 1
Accumulation of metabolic risk factors was associated with higher risk of MACE in patients with recent acute coronary syndrome. Alirocumab reduced MACE consistently, but aRR increased with number of metabolic risk factors.
Categories: Endocrinology, Latest HeadlinesTweet-
New—Metabolic risk factors and effect of #alirocumab on #cardiovascular events after acute #coronary syndrome: a post-hoc analysis of the #ODYSSEY OUTCOMES randomised controlled trial https://t.co/exUIR7Tdp2 #PCSK9 inhibitor
-
-
Mashup Score: 1Targeting PCSK9 inhibitors to those who will benefit most - 2 year(s) ago
In The Lancet Diabetes & Endocrinology, Petr Ostadal and colleagues report a post-hoc subgroup analysis of the ODYSSEY OUTCOMES trial assessing the contribution of metabolic risk factors to future cardiovascular events in patients with recent acute coronary syndrome.1 This large cardiovascular outcome trial, describes the benefits of additional LDL cholesterol reduction with the PCSK9 inhibitor…
Categories: Endocrinology, Latest HeadlinesTweet-
Traci A Turner & Evan A Stein comment on: Targeting #PCSK9 inhibitors to those who will benefit most https://t.co/5plRd3SdPg #alirocumab #ODYSSEY OUTCOMES https://t.co/6YHHA47OIc
-
-
Mashup Score: 0
This Viewpoint describes the implications of pending legislature authorizing Medicaid payments for whole-genome sequencing.
Source: jamanetwork.comCategories: Latest Headlines, PediatricsTweet-
Ending the Diagnostic #Odyssey: Is whole #genome #sequencing the answer? Viewpoint by @Asthma3Ways https://t.co/kwYym73iyM @PROMoTeR_DPM #WGS #PrecisionMedicine
-
-
Mashup Score: 0
This Viewpoint describes the implications of pending legislature authorizing Medicaid payments for whole-genome sequencing.
Source: jamanetwork.comCategories: Latest Headlines, PediatricsTweet-
Ending the Diagnostic #Odyssey: Is whole #genome #sequencing the answer? Viewpoint by @Asthma3Ways https://t.co/JK5JBX3Yr3 @PROMoTeR_DPM #WGS #PrecisionMedicine
-
-
Mashup Score: 0
New data from the ODYSSEY Outcomes trial show that alirocumab is effective at reducing risk for any stroke without increasing risk for hemorrhagic stroke.In a cohort of 18,924 patients with recent ACS and elevated LDL despite intensive statin therapy, alirocumab (Praluent, Sanofi/Regeneron) was effective in reducing the risk for any stroke (HR = 0.72; 95% CI, 0.57-0.91) and ischemic stroke (HR =
Source: www.healio.comCategories: Cardiology News and JournalsTweet-
Findings from the #ODYSSEY outcomes trial showed that #alirocumab may reduce #stroke risk without increasing odds of #hemorrhage, according to research published in @CircAHA #AHAJournals @American_Heart https://t.co/Jk5kYotutm
-
In the May Issue: Metabolic risk factors and effect of #alirocumab on #cardiovascular events after acute #coronary syndrome: a post-hoc analysis of the #ODYSSEY OUTCOMES randomised controlled trial https://t.co/exUIR7Tdp2 #PCSK9 inhibitor #CVD #ACS